Medicines for Europe Country Specific Market Access Policies

ISPOR 2016 EU – Value Added Medicines

ispor2

Healthcare System Inefficiencies Related To Medicines: Any Potential Room For Improvement?

OPEN

ispor3

Value Added Medicines: The Need to Establish One Common Terminology for Repurposed Medicines

OPEN

ispor4

Value Added Medicines: What Value Repurposed Medicines Might Bring to Society?

OPEN

ispor5

Obstacles for Adoption of Value Added Medicines: Call for Policy Changes for Value Recognition of Repurposed Medicines

OPEN

Essential Medicines for Universal Health Coverage

Medicines for Europe’s Contribution to WHO’s Biological Qualifier (BQ) Developments (PRESENTATION and SPEECH)

picto-presentationpicto-speech

 

 

 

18 October 2016
Suzette Kox
Senior Director International
Biosimilar Medicines Group

Understanding the Science of Extrapolation and Defining Interchangeability – Dr. Elena Wolff-Holz, EULAR Symposium London

Value Added Medicines: Rethink, Reinvent & Optimize Medicines, Improving Patient Health & Access

EGA-EBG Summary Position Regarding the WHO Biologic Qualifier Proposal (INN Working Doc. 14.342)

Sans-titre-4

Biosimilar Product Labelling

To view the full paper, please click here.

The value of generic medicines

The value of generic medicines

Read more about the value of generic medicines

PDF version

or download the presentation

PPT version

 

EGA-EBG Considerations on WHO’s BQ Proposal – Suzette Kox, WHO INN Open Session with Stakeholders, Geneva, 13 October 2015 (PPT)

20151013_WHO_INN_meeting-EBG_SK

Medicines For Europe